Teprotumumab is named as an intervention in 3 current clinical trials in our China, UK and USA registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Amgen (1). The most-studied condition is Thyroid Eye Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
NCT07265258 · ClinicalTrials.gov ↗ · Thyroid Eye Disease
|
Phase 4 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | China |
|
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
NCT07594912 · ClinicalTrials.gov ↗ · Thyroid Eye Disease, TED, Graves Ophthalmopathy, Optic Neuropathy
|
Phase 2 | Not yet open | Sun Yat-sen University | China |
|
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619 · ClinicalTrials.gov ↗ · Thyroid Eye Disease
|
Phase 3 | Active, closed | Amgen | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Teprotumumab on the HPRA medicines list.
No entry for Teprotumumab in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Amgen | 1 |
| Sun Yat-sen University | 1 |
| Innovent Biologics (Suzhou) Co. Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in UK | 1 | 0 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, UK and USA registers name Teprotumumab (also registered as Teprotumumab N01) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Amgen (1), Sun Yat-sen University (1) and Innovent Biologics (Suzhou) Co. Ltd (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Teprotumumab, for example TEPEZZA 500 mg powder for concentrate for solution for infusion (Amgen Europe B.V.,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Teprotumumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Teprotumumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Teprotumumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Teprotumumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.